ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ribupatide

Also written as “HRS9531”, “HRS9531 injection” and “HRS9531 Tablet”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic · Atherosclerosis · Fatty Liver, led by 2 companies.

Drug pageRibupatide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 30, 202438 company-led studies, 19 open or runningLicense: Hengrui → Kailera, May 2024Next primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicineits history only3214 open or runningphase 3since Apr 30, 2024Nov 29, 2021Dec 2026phase 3 · NCT06994650
Kailera65 open or runningphase 3since Dec 9, 2025Jun 23, 2025May 2027phase 2 · NCT07458269
  • Named in Jiangsu HengRui Medicine’s own pipeline as Ribupatide, phase 4, as of Jul 31, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Kailera only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 2024Kailera licensed it from HengruiLicenseEverywhere outside Greater China · agreed · Kailera Therapeutics (release)
  2. Jun 23, 2025First study: phase 1 study in OverweightFirst studyNCT07044401 · 51 enrolled · United States
  3. Jul 10, 2025Named ribupatideINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HRS9531
  4. Dec 9, 20253 phase 3 studies in ObesityPhase 3 reachedNCT07284979, NCT07284901, NCT07284875
  5. Mar 3, 2026Phase 2 study in ObesityNCT07458269 · 264 enrolled · United States
  6. Aug 25, 2026Phase 1 study in Kidney Failure, ChronicNCT07793929 · 32 planned · United States

Ahead

  1. May 2027Primary completion: phase 2 study in ObesityNCT07458269
  2. Feb 2028Primary completion: phase 3 study in ObesityNCT07284875
  3. Feb 8, 2028Primary completion: phase 1 study in Kidney Failure, ChronicNCT07793929
  4. Mar 2028Primary completion: phase 3 study in ObesityNCT07284979

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Kailera leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07793929Kidney Failure, Chronic · United States1RecruitingFeb 8, 202832
NCT07458269Obesity · United States2Active, not recruitingMay 2027264
NCT07284979Obesity · United States, Australia, Bulgaria and more3Active, not recruitingMar 20281,270
NCT07284901Obesity · United States, Argentina, Australia and more3Active, not recruitingMar 27, 20281,270
NCT07284875Obesity · United States, Argentina, Australia and more3Active, not recruitingFeb 20282,530
NCT07044401Overweight · United States1CompletedNov 13, 202551

How it is read

Names in the registry

  • “HRS9531”, 16 entries
  • “HRS9531 injection”, 14 entries
  • “HRS9531 Tablet”, 9 entries
  • “HRS9531 Injection”, 6 entries
  • “Ribupatide”, 5 entries

Codes read as this program: HRS9531.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.